Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ayisha Sharma

Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from the University College London. Ayisha is especially interested in the clinical landscape for rare diseases. Outside of work, she has written for several lifestyle and culture publications including The Kraze and M&S Vmag.

Latest From Ayisha Sharma

Valneva Confirms Step Back From COVID-19 Vaccine Development

The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.

Coronavirus COVID-19 Vaccines

Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma

Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.

Emerging Company Profile Companies

Radioligands Advance Radiotherapy Premise With Greater Precision

With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer. 

Innovation Research & Development

Merck Takes A New Shot At Alzheimer’s With Cerevance Deal

The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.

Deals Neurology

French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert

David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.

Leadership Reimbursement

GSK Makes ADC Pipeline Comeback With Mersana Deal

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.

Companies Deals
See All
UsernamePublicRestriction

Register